1 / 8

The ON going T elmisartan A lone and in

ONTARGET. The ON going T elmisartan A lone and in combination with R amipril G lobal E ndpoint T rial. Salim Yusuf, Koon K. Teo, Janice Pogue, Leanne Dyal, and Ingrid Copland, Population Health Research Institute and Investigators. Yusuf , et al. N ENGL J MED.358;15:1547-1559.

gil-brady
Download Presentation

The ON going T elmisartan A lone and in

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ONTARGET The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial Salim Yusuf, Koon K. Teo, Janice Pogue, Leanne Dyal, and Ingrid Copland, Population Health Research Institute and Investigators Yusuf, et al. N ENGL J MED.358;15:1547-1559

  2. ONTARGET Change in BP (mmHg) Yusuf, et al. N ENGL J MED.358;15:1547-1559

  3. Telmisartan Ramipril Cumulative Hazard Rates Years of Follow-up NO. at Risk Telmisartan 6478 8542 7954 7384 6909 6254 Ramipril 8576 7796 7165 6681 ONTARGET Time to Permanent Discontinuation of Study Medication Yusuf, et al. N ENGL J MED.358;15:1547-1559

  4. ONTARGET Reasons for Permanently Stopping Study Medications Yusuf, et al. N ENGL J MED.358;15:1547-1559

  5. ONTARGET Time to Primary Outcome Telmisartan Cumulative Hazard Rates Ramipril Years of Follow-up NO. at Risk 8176 7778 7420 7051 8542 Telmisartan 8214 7832 7473 7095 8576 Ramipril Yusuf, et al. N ENGL J MED.358;15:1547-1559

  6. ONTARGET Primary Outcome & HOPE Primary Outcome Yusuf, et al. N ENGL J MED.358;15:1547-1559

  7. ONTARGET Time to Primary Outcome Ramipril Cumulative Hazard Rates Tel.&Ram. Years of Follow-up NO. at Risk 8576 8214 7832 7473 7095 Ramipril 8502 8134 7740 7377 7023 Tel.&Ram. Yusuf, et al. N ENGL J MED.358;15:1547-1559

  8. ONTARGET Reasons for Permanently Stopping Study Medications Yusuf, et al. N ENGL J MED.358;15:1547-1559

More Related